Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 2, 2025International Journal of HematologyOpen Access

A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLL

View Full Paper
Ask AI
Bookmark
Share

Authors

SKShigeru KusumotoAichi Cancer Center

Discussion

Loading...

Member takes

Implication

Clinical trial demonstrates 60% complete remission in Japanese patients with chronic lymphocytic leukemia, suggesting promising efficacy and safety.

Key Points

  • Complete remission rate reached 60% among patients treated with ibrutinib and venetoclax, highlighting strong efficacy.
  • Median progression-free survival not estimated, yet suggests potential for prolonged treatment effects in chronic lymphocytic leukemia.
  • The phase 2 clinical trial evaluated along with treatment-emergent adverse events, with 70% experiencing grade 3/4 reactions.
  • These findings indicate a favorable benefit-risk profile, warranting further research in chronic lymphocytic leukemia management.

Cite This Study

Shigeru Kusumoto (2025) studied this question.

synapsesocial.com/papers/692e3d706c9b3ab28c186fa9https://doi.org/10.1007/s12185-025-04114-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of fixed-duration venetoclax plus obinutuzumab in untreated Japanese CLL and SLL: a phase 2 study2025
  2. 2Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma2025
  3. 3Ibrutinib with Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Phase II Study2026
  4. 4Clinical Experience with Venetoclax and Its Safety in Patients with Chronic Lymphocytic Leukemia in Later Lines of Treatment: A Multicenter Analysis from Slovakia2026
  5. 5Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance2024 · 1 citations